IconOVir Bio

Next-generation oncolytic virus therapies for solid tumors.

San Diego, United States · Founded 2018 · $97.2M raised

Employees
11–50
Founded
2018
Business Model
B2B
Total Funding
$97.2M
Last Round
$20.2M Venture RoundJun 2024
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy for the treatment of cancer. Its proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O'Shea, Ph.D., of the Salk Institute, and is designed to selectively replicate within and destroy tumor cells while sparing normal tissue. The company was founded by Two River Group, chaired by Arie Belldegrun, M.D., FACS — the team behind Kite Pharma and Allogene Therapeutics — and is focused on developing next-generation oncolytic viruses engineered for superior potency and immune engagement in solid tumors.

Summary

IconOVir Bio is a Biotech company based in San Diego, United States, founded in 2018. It has raised $97.2M in total across 2 rounds, most recently a $20.2M Venture Round in Jun 2024. Investors include Vida Ventures, Nextech Invest and Two River Group.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundJun 2024
$20.2M

Sign up to see all 2 events

Funding: Series A through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Mirador Therapeutics

Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...

San Diego, United States11–50Biotech, Drug Discovery
Series BTotal funding$650.0MOct 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

IconOVir Bio on Indexed.vc
<a href="https://indexed.vc/companies/iconovir-bio"><img src="https://indexed.vc/api/badge/company/iconovir-bio" alt="IconOVir Bio on Indexed.vc" width="260" height="76" /></a>